Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Sponsor: University of Roma La Sapienza
Summary
This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.
Official title: Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN. REBORN Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2020-09-14
Completion Date
2025-12-31
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Somatostatin analog; chemotherapy
According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
Locations (1)
Andrea M Isidori
Rome, Italy, Italy